January 21, 2017 5:02 PM ET


Company Overview of Intralytix, Inc.

Company Overview

Intralytix, Inc. is a biotechnology company that focuses on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings. The company offers various food safety solutions, such as ListShield, a non-chemical antimicrobial preparation solution for eliminating or significantly reducing the levels of Listeria monocytogenes on non-food contact equipment, surfaces, etc. in food processing plants and other food establishments. It also offers EcoShield, an antimicrobial preparation solution for controlling Escherichia coli O157:H7 and is used in the production of red meat parts and trims prior to grinding as a pro...

The Columbus Center

701 East Pratt Street

Baltimore, MD 21202

United States

Founded in 1998





Key Executives for Intralytix, Inc.

Co-Founder, Chief Executive Officer and President
Chief Scientist and Vice President of Research & Development
Compensation as of Fiscal Year 2016.

Intralytix, Inc. Key Developments

Ferring Pharmaceuticals and Intralytix, Inc. to Partner on Therapies for Drug Resistant Infections

Ferring Pharmaceuticals announced that it will partner with Intralytix Inc. on the development of viral therapies for multi-drug resistant bacterial infections and other conditions. The therapies will be based on a virus called bacteriophage which particularly infects and destroys bacteria. Unlike conventional antibiotics, this sort of treatments does not affect beneficial bacteria and addresses the growing issue of drug resistance. Under the collaboration, the companies will jointly investigate therapies to regulate the microorganisms present in the female reproductive tract, oral cavity and skin.

Ferring Pharmaceuticals to Collaborate with Intralytix, Inc

Ferring Pharmaceuticals announced that it will collaborate with Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD). In the collaboration announced, Intralytix will assist Ferring in formulating and manufacturing the bacteriophages for use in clinical trials, which are expected to begin as soon as 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intralytix, Inc., please visit www.intralytix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.